Technology | October 03, 2013

Esteya Electronic Brachytherapy System Receives FDA 510(k) Clearance

Esteya, brachytherapy, Esteya Electronic Brachytherapy System, Nucletron

Esteya Electronic Brachytherapy System

October 3, 2013 – Esteya, an electronic brachytherapy system, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA), enabling medical centers in the United States to offer their patients with skin cancer a new treatment option.

Esteya is a new approach for high precision skin cancer treatment. The system relies on a small, high dose rate (HDR) to apply radiation directly to the cancerous site. This direct delivery enables Esteya to focus more therapeutic radiation on the disease target and to minimize radiation to surrounding tissues and organs. Electronic brachytherapy is well-suited for treating skin lesions, such as basal cell or squamous cell carcinoma, achieving a greater than 95 percent cure rate for this technique.

"The interest in Esteya among radiation oncologists during the American Society for Radiation Oncology annual meeting last week in Atlanta was encouraging," John Lapre, EVP of Brachytherapy at Elekta, commented. "They appreciated the efficient workflow, easy patient set-up, and the short treatment delivery time. They also cited the accessibility of Esteya — due to its compact design and reduced shielding requirements — allowing treatment to occur virtually anywhere patients are seen within the clinic."

The first installations of Esteya in the United States are scheduled to occur in the next few months.

For more information: www.esteya.com

Related Content

New Guideline for Prostate Cancer Supports Shortened Radiation Therapy
News | Prostate Cancer | October 12, 2018
Three prominent medical societies issued a new clinical guideline for physicians treating men with early-stage prostate...
Surgery, Radiation Therapy Equally Effective in Treating Oropharyngeal Cancer
News | Radiation Therapy | October 09, 2018
A new study by researchers at UT Southwestern Medical Center found no major long-term differences in the effectiveness...
ASTRO 2018 Radiation Therapy Clinical Trials
Feature | ASTRO | October 08, 2018
October 8, 2018 — The American Society for Radiation Oncology (ASTRO) announced the 10 top-rated clinical studies tha
Videos | Treatment Planning | October 08, 2018
Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology at Henry Ford Health System, descri
ViewRay and Miami Cancer Institute Host Symposium on MR-Guided Radiation Therapy
News | Image Guided Radiation Therapy (IGRT) | October 05, 2018
October 5, 2018 — Leading oncology experts from around the world recently met to discuss the integration of...
Videos | Treatment Planning | October 05, 2018
Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology at Henry Ford Health System, descri
Videos | Image Guided Radiation Therapy (IGRT) | October 04, 2018
Carrie Glide-Hurst, Ph.D., and Benjamin Movsas, M.D., discuss Henry Ford Hospital's involvement in a national clinica
Miami Cancer Institute

The Miami Cancer Institute team.

Sponsored Content | Case Study | Radiation Therapy | October 04, 2018
Miami Cancer Institute, a part of Baptist Health South Florida, is a state-of-the-art center that serves as the primary...
RaySearch Releases Version 2B of  RayCare Oncology Information System
Technology | Oncology Information Management Systems (OIMS) | October 04, 2018
RaySearch Laboratories AB has released RayCare 2B, the latest version of its oncology information system (OIS). RayCare...
Xoft Electronic Brachytherapy System Effective Long-Term for Early-Stage Breast Cancer
News | Brachytherapy Systems, Women's Healthcare | October 02, 2018
Breast cancer recurrence rates for patients treated with the Xoft Axxent Electronic Brachytherapy (eBx) System that...